Pinnacle Blooms Receives $70 Mn Investment Offer to Scale GPT-OS Paediatric Therapy Platform

The structured Series A proposal, advised by Yukon Capital, reflects rising investor focus on data-driven and scalable paediatric therapy infrastructure.

Pinnacle Blooms Network, the paediatric therapy arm of Bharath Healthcare Laboratories, has received a $70 million investment offer from a global healthcare-focused institutional fund to accelerate the expansion of its AI-powered child development platform, GPT-OS.

The structured Series A proposal, advised by Yukon Capital, reflects rising investor focus on data-driven and scalable paediatric therapy infrastructure.

If finalised, the two-phase investment would be among the largest early-stage financings in Asia’s child development and therapy segment. The capital is expected to support Pinnacle’s plan to expand its physical network from 70 to 300 therapy centres over the next 24 months, while also scaling home-based therapeutic solutions and manufacturing of sensory-driven therapy environments.

Pinnacle Blooms currently operates what it describes as India’s largest paediatric therapy ecosystem, delivering more than 20 million one-on-one clinical therapy sessions addressing autism spectrum disorders, speech delays, ADHD, and related developmental conditions. Its proprietary GPT-OS platform functions as a digital therapeutic operating system designed to measure, personalise, and track therapy outcomes across cognitive, behavioural, motor, and speech domains.

The GPT-OS architecture integrates multiple clinical and analytical modules, including diagnostic and prognostic tools, AI-assisted therapy planning, outcome measurement frameworks such as AbilityScore, readiness indexes, and multisensory therapy environments. According to the company, the system enables continuous tracking of developmental progress using structured clinical data.

Aneesh Madhav, Chief Executive Officer at Yukon Capital, said the investment interest reflects a shift toward outcome-measurable developmental health models. “Pinnacle has addressed the long-standing challenge of scaling therapy while retaining clinical rigor and human involvement,” he said.

Bharath Healthcare Laboratories Founder and Chairman Dr. Koti Reddy Saripalli stated that the platform was built around longitudinal learning from therapy sessions. “Each session contributed to improving the system’s clinical intelligence,” he said.

Clinical validation remains a key focus for the company. Pinnacle reports that its platform is supported by a dataset of over 20 million sessions structured in line with WHO ICD-11, ICF, and ICHI standards. The organisation holds ISO 13485:2016 and ISO/IEC 27001:2022 certifications and is currently conducting 12 clinical studies covering developmental outcomes, AI optimisation, sensory therapy, and parental co-therapy models.

Looking ahead, Pinnacle projects further expansion to more than 600 centres over four years and is exploring international pilots across Southeast Asia and the GCC. Analysts tracking the sector note that global paediatric therapy, forecast to cross $50 billion by 2030, is increasingly drawing capital toward AI-led platforms focused on measurable outcomes.

Stay tuned for more such updates on Digital Health News